Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis

OBJECTIVE: Abatacept is a biological disease-modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (RA) and modulates the costimulatory signal by cluster of differentiation (CD)28:CD80/CD86 interaction required for T cell activation. Since CD28-mediated signalling regul...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:RMD Open
Päätekijät: Ghannam, Khetam, Martinez Gamboa, Lorena, Kedor, Claudia, Spengler, Lydia, Kuckelkorn, Ulrike, Häupl, Thomas, Burmester, Gerd, Feist, Eugen
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Rheumatoid Arthritis
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7547540/
https://ncbi.nlm.nih.gov/pubmed/32998980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001248
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia